Abstract 1612
Background
Patients (pts) enrolled in ECT with CI are mainly selected based on tumor type. Genomic markers are informative in few cases. We assessed microenvironment markers as prescreening tool to identify pts with higher chances of clinical benefit from CI.
Methods
Pts treated with anti PD1/PDL1 drugs in monotherapy or in combination with other CI in ECT at our centre were evaluated for TILs on hematoxylin-eosin stained sections and PDL1 expression in tumor (tumcells) and immune cells (immcells) by immunohistochemistry (SP263 antibody). Results were correlated with clinical outcomes.
Results
From June 16 to June 17, 64 pts were recruited. TILs and PDL1 expression were available for all and 39 pts, respectively. Tumor types were melanoma (16 pts), neuroendocrine (9), gyne (8), breast (5), H&N (4), others (22). In total, 38 pts received anti PD1/PDL1 in monotherapy, the rest received anti PD1/PDL1 based combinations (12 pts had prior CI treatment). Response rate (RR) was 22%; median PFS was 4 months (m) (CI95% 3.30-5.57). We found no differences in PDL1 expression in tumcells according to tumor type (Kruskal test p = 0.33) and a weak correlation between TILs and PDL1 in tumcells (Pearson 0.44; p = 0.004) or immcells (Pearson 0.57; p = 0.0001). Median TILs was 7% (range 1-90), with no difference according to tumor type (Kruskal test p = 0.45). Median TILs was higher in pts with response to CI (17.5% v 5%, Kruskal test p = 0.06). RR in pts with TILs ≥7% was 32% v 9% if TILs <7% (Fisher test p = 0.06). In a multivariable logistic model adjusting for tumor type and CI regimen, RR was significantly higher in pts with TILs ≥7% (odds ratio 8.2; p = 0.05). Median PFS in pts with TILs ≥7% was 5 m v 3.7 m if TILs <7% (HR = 0.57 in a multivariable Cox model, p = 0.06). In univariate models, there was a trend for higher RR if PDL1 ≥1% in tumcells (35% v 12%, fisher test p = 0.28) or if PDL1 ≥1% in immcells (35% v 16%, fisher test p = 0.27). PFS was not correlated with PDL1 expression.
Conclusions
Quantifying TILs is a simple prescreening strategy that may help select pts for CI therapy in ECT from otherwise unselected population. The value of adding PDL1 expression needs further investigation.
Clinical trial identification
Legal entity responsible for the study
VHIO.
Funding
Has not received any funding.
Editorial Acknowledgement
Disclosure
J. Tabernero: Advisory boards: Bayer, Boehringer Ingelheim, Genentech/Roche, Lilly, MSD, Merck Serono, Merrimack, Novartis, Peptomyc, Roche, Sanofi, Symphogen, Taiho. All other authors have declared no conflicts of interest.
Resources from the same session
5964 - Longitudinal Assessment of Multiplex Patient-Specific ctDNA Biomarkers in Bladder Cancer for Diagnosis, Surveillance, and Recurrence
Presenter: Karin Birkenkamp-Demtröder
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
2197 - Distinct functional consequences of HER2 gene amplification in colorectal and lung adenocarcinomas
Presenter: Evgeny Imyanitov
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
2422 - Role of AR-V7 and AR-FL in resistance to hormonal therapy in mCRPC: independent actors or reciprocal drivers? A translational study by Meet-Uro group
Presenter: Marzia Del Re
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
2750 - Validation of a 90-gene assay for tissue origin diagnosis of brain metastases
Presenter: Yulong Zheng
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
2960 - Development of a Pan-Cancer Biomarker Panel for Improved Detection of MSI Across all Cancer Types
Presenter: Jeff Bacher
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
3791 - bMSI better predicts the responses to immune checkpoint inhibitors (ICI) than MMR/MSI from historical tissue specimens in metastatic gastrointestinal cancer patients
Presenter: Zhenghang Wang
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
5189 - Vall d’Hebron Institute of Oncology (VHIO) Immuno-Oncology prognostic index (VIO): a new tool for improved patient (pt) selection in Phase 1 (Ph1) trials with Immune Checkpoint Inhibitors (ICI).
Presenter: Cinta Hierro
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
5372 - Augmenting TNM Staging with Machine Learning-based Immune Profiling for Improved Prognosis Prediction in Muscle-Invasive Bladder Cancer Patients
Presenter: Nicolas Brieu
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
2249 - HPV circulating tumor DNA as predictive biomarker of sustained response to chemotherapy in advanced anal carcinoma
Presenter: Alice Bernard-Tessier
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
2287 - Predicting toxicity and response to pembrolizumab (P) through germline genomic HLA class I analysis
Presenter: Marco Iafolla
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract